TSRL, Inc. is a preclinical drug development accelerator located in Ann Arbor, Michigan that aims to advance promising compounds for treating severe and drug-resistant infections. The document outlines TSRL's capabilities including analytical testing, pharmacokinetics studies, formulation development, and efficacy modeling. It also discusses funding opportunities through Small Business Innovation Research grants from the National Institute of Allergy and Infectious Diseases as well as other NIH research grants that could support infectious disease drug development.

1. Inception Pre-lead Lead IND NDA
3-5 years 1 year 2 years 5 years
ValueofOpportunity
Development Timeline“Valley of Death”
Value Inflection
Drug
Discovery
10k-30k
Lead
Selection
30-60
Preclinical
Development
10-20
Phase I
5-10
Phase II
2-5
Phase III
2
Approval
1
©2016 TSRL, Inc.
# Compounds
Spotlight:
About Us We are a privately-owned pharmaceutical accelerator based in
Ann Arbor, Michigan with a 7,200 sq. ft. AAALAC-accredited facility with 5,000 sq.
ft. of wet lab space including analytical, formulation, cell culture and in vivo
testing capabilities.
Many therapeutic assets are struggling to find funding to
move past the “Valley of Death.”
Collaborate » Bring together interdisciplinary science & business acumen
Increase visibility » Engage industry sponsors as they seek new pipeline
candidates, receive valuable commercial & technical feedback
Improve efficiency » Achieve study timelines based on project goals and
generate quality, reproducible data
The Challenge
The Solution Increase the Strength of Your Preclinical Package
bd@tsrlinc.com  734-663-4233 x224  www.tsrlinc.com ©TSRL 2016

2. NIAID SBIR
Awardees
2015, 2014,
2013, 2011,
2010
Spotlight:
Advancing lead compounds in infectious diseases
Open up preclinical funding opportunities
About Us- TSRL, Inc. is a preclinical accelerator based in Ann Arbor,
Michigan. Our mission to advance promising compounds for treating
severe and multi-drug resistant infections.
Our R & D Capabilities:
 LC/MS/MS, ELISA, HPLC-UV analysis
 Chemical & metabolic stability
 Metabolite identification (ID)
 Tissue distribution
 Pharmacokinetics
 Permeability
 Formulation
 Efficacy models
 Exploratory toxicology
BD & Marketing Capabilities:
 Competitive analysis
 Commercialization plan writing
 Pitch deck formation
 Website management
 Social media management
bd@tsrlinc.com  734-663-4233  www.tsrlinc.com
Small Business Research Grants (SBIR/STTR)
» To foster scientific collaboration between small business concerns
and research institutions
» NIAID-approved waiver topics include novel anti-infective drugs
» Phase I: ≤$300k/yr for two yrs; Phase II: ≤$1m/yr for three yrs
NIH Research Grants – Omnibus Solicitations, BAAs and More!
R01 » Supports specific projects within interests of investigator
» ≤$500k direct costs/yr + ≤40% indirect costs for up to five yrs
» Ex: Partnerships for Countermeasures Against Select Pathogens
R21 » Supports new, exploratory and developmental research projects
» ≤$275k direct costs/yr + ≤40% indirect costs for up to two yrs